Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts

NCT: NCT07197541 · ACTIVE_NOT_RECRUITING

NCT IDNCT07197541
StatusACTIVE_NOT_RECRUITING
Start Date2025-10-01
Completion2026-11-01
SponsorSecond Affiliated Hospital, Zhejiang University, School of Medicine (OTHER)
First posted
Last updated

Brief Summary

All patients were treated as self-control. Half of the warts received bleomycin injection and the other half received pingyangmycin injection for 24 weeks. During the treatment period, before each injection, photos of the skin lesions must be taken, the diameter of the skin lesions must be measured, the DLQI(Dermatology Life Quality Index) and NRS scores(NRS scores) must be filled in, and adverse events must be recorded. Before the first treatment, HPV(Human Papilloma virus) virus typing is performed on the warts.

Frequently Asked Questions

What is A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts?

A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts is a clinical trial registered under NCT07197541. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT07197541?

The current status of NCT07197541 (A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts) is: ACTIVE_NOT_RECRUITING.

When did A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts start?

A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts started on 2025-10-01.

Related Devices

K172091CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A/B Typing Kit, CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A Subtyping Kit, CDC Human Influenza Virus Real-time RT-PCR, Influenza B Lineage Genotyping Kit, CDC Human Influenza Virus Real-time RT-PCR, Influenza A/H5 Subtyping KitCenters for Disease Control and Prevention K190302CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A/B Typing Kit, CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A Subtyping Kit, CDC Human Influenza Virus Real-time RT-PCR, Influenza B Lineage Genotyping Kit, CDC Human Influenza Virus Real-time RT-PCR, Influenza A/HS Subtyping KitCenters for Disease Control and Prevention K200370CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A/B Typing Kit, CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel, Influenza A Subtyping Kit, CDC Human Influenza Virus Real-time RT-PCR, Influenza A/H5 Subtyping KitCenters for Disease Control and Prevention K243274CDC Human Influenza Virus Real-Time RT-PCR Diagnostic Panel: Influenza A/B Typing Kit (VER 2); Influenza A SubTyping Kit (VER 4); Influenza B Genotyping Kit (VER 1.1 and 2); and Influenza A/H5 Subtyping Kit (VER 4)Centers for Disease Control and Prevention K243931CDC Human Influenza Virus Real-time RT-PCR Diagnostic Panel: Influenza A/B Typing Kit (VER 2); Influenza A Subtyping Kit (VER 4); Influenza B Lineage Genotyping Kit (VER 1.1 and 2); and Influenza A/H5 Subtyping Kit (VER 4)Centers for Disease Control and Prevention

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑